Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician, Consumer",Pembrolizumab,"Breast cancer, triple negative, early Stage II or III, neoadjuvant treatment followed by adjuvant monotherapy",Pembrolizumab (Keytruda),Options for investment,Hospital,Oncology Agents and Immunosuppressants
